- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged(NVOH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NVOH
11/20/2026: NVOH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) provides targeted exposure to Novo Nordisk's equity performance while neutralizing daily currency fluctuations via swap overlays. Its main strengths include a cost-effective 0.19% expense ratio and a specialized structure that eliminates foreign exchange noise for US investors. The fund functions primarily as a concentrated single-stock satellite holding rather than a diversified core investment. Key risks center on extreme single-stock concentration, regulatory pricing pressures, and lower secondary market liquidity. It suits growth-oriented investors looking for clean, currency-hedged access to a leading global pharmaceutical firm while monitoring execution spreads.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Provides concentrated exposure to a high-growth global pharmaceutical leader focused on blockbuster metabolic therapies. |
| Momentum investor | Strong fit while signal remains positive | Allows tactical participation in Novo Nordisk's price momentum when technical breakout conditions persist. |
| Value investor | Mixed fit | Valuation is often elevated due to strong secular growth expectations in obesity and diabetes treatment markets. |
| Dividend/Income investor | Mixed fit | Offers a moderate dividend yield derived from underlying payouts, though capital appreciation is the primary objective. |
| Low-risk investor | Weak fit | Concentrated single-stock exposure introduces substantial company-specific and clinical trial risks. |
Investor Profile
Ideal Investor Profile
Tactical or long-term investors seeking concentrated exposure to Novo Nordisk who specifically wish to neutralize USD/DKK currency risk.
Suitability
Best suited for sophisticated retail or advisory investors comfortable with single-stock risk and lower secondary market liquidity.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium / high | Single-stock concentration leads to sharp price swings relative to diversified market baskets. |
| Market risk | High | Performance relies entirely on the market sentiment and business execution of a single underlying company. |
| Concentration | High | The portfolio is essentially 100% exposed to Novo Nordisk, offering zero sector or stock diversification. |
| Tracking/expense | Low | Derivative swap execution costs and currency tracking error are minimal given the 0.19% expense ratio. |
| Liquidity | Medium / high | Low assets under management and modest trading volume can result in wider spreads during market stress. |
| Business/sector quality | Low | Novo Nordisk is a world-class pharmaceutical entity with robust balance sheet metrics and market leadership. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
Exhibits volatility characteristic of a single high-growth pharmaceutical stock, amplified by concentrated positioning.
Market Risk
Vulnerable to equity market sell-offs, sector-specific healthcare corrections, and company-level pipeline or earnings setbacks.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | Novo Nordisk A/S Sponsored ADR Class B | 93.55 | Provides direct core economic exposure to Novo Nordisk's global pharmaceutical business. |
| Cash/collateral | U.S. Dollar / Collateral Reserve | 6.45 | Maintains liquidity for daily operational costs, margin needs, and swap settlements. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit -46.31% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

